ELEVAI Biosciences, a Subsidiary of ELEVAI Labs Inc., Expands Patent Portfolio With Two New Filings for El-22 in Muscle Loss Treatment for Obese Patients, Including Glp-1 Receptor Agonist Combinations

THOMSON REUTERS
03 Oct 2024

ELEVAI Biosciences, a Subsidiary of ELEVAI Labs Inc., Expands Patent Portfolio With Two New Filings for El-22 in Muscle Loss Treatment for Obese Patients, Including Glp-1 Receptor Agonist Combinations

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10